The latest trading session saw Goldman Sachs (GS) ending at $458.15, denoting a -0.91% adjustment from its last day's close. The stock's change was less than the S&P 500's daily loss of 0.74%. Elsewhere, the Dow lost 1.53%, while the tech-heavy Nasdaq lost 0.39%.Heading into today, shares of the investment bank had gained 9.3% over the past month, outpacing the Finance sector's gain of 3.93% and the S&P 500's gain of 6.06% in that time.The upcoming earnings release of Goldman Sachs will be of great interest ...

 VALLETTA, Malta, May 23, 2024 /PRNewswire/ -- Kindred Group plc (Kindred) hereby announces that it, on 21 May 2024, has received three notifications of major holding from The Goldman Sachs Group, Inc., a company with its registered office in Wilmington, USA. The notifications relate to two increases and a following decrease in the number of shares and voting rights in Kindred held by the Goldman Sachs Group.According to the last notification, the Goldman Sachs Group held 5.12% of the shares and voting righ ...

Goldman Sachs CEO David Solomon said Wednesday he does not expect the Federal Reserve to cut interest rates this year.“I’m still at zero cuts,” Solomon said at a Boston College event. “I think we’re set up for stickier inflation.”His comments came after Federal Reserve policymakers said on Tuesday the central bank should wait several more months to ensure that inflation really is back on track to its 2% target before cutting interest rates.“I’m still at zero cuts,” Goldman CEO David Solomon said at a Boston ...

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Goldman Sachs (GS) .Goldman currently has an average brokerage recommendat ...

Key PointsThree financial stocks have been outperforming as the Fed seems farther from interest rate cuts than the market thought.Gaining fundamental momentum from rising net interest income, investors would benefit from focusing on some of these companies.One specific industry is seeing tons of customer asset growth, and analysts are fearless in pushing for 31.8% EPS growth this year.5 stocks we like better than Charles SchwabAre there any safe stocks out there? Investors need to align their portfolios wit ...

The investment bank industry is set to flourish in 2024 following a rebound in corporate debt and equity issuances and deal-making activities, which is expected to increase investment banking fees.After a sustained weakness in underwriting, IPOs and deal-making activities since 2022 due to geopolitical tensions, global supply-chain disruptions, aggressive monetary policy tightening worldwide to control inflation and potential recession risks, green shoots in advisory and underwriting businesses are visible ...

Core Insights - Goldman Sachs plans to increase its lending services to private equity and asset managers, aiming to fill gaps left by regional banks and the sale of Credit Suisse [1] - The private equity market is expected to grow due to record-high fundraising, making it a strategic focus for Goldman Sachs [1] - The bank's asset-secured lending strategy will enhance its financing business in fixed income, currency, commodities, and equities [1] Lending Expansion - Goldman Sachs has seen significant growth in its deposit base over the past seven years and is aligning its asset growth with this expansion [2] - In 2023, Goldman acquired a $15 billion loan portfolio from the failed Signature Bank, which includes loans to private equity firms and venture capital funds [2] - The bank plans to expand its lending operations into Europe, the U.K., and Asia after strengthening its U.S. operations [2] Business Restructuring - Goldman Sachs is refocusing on its core strengths in investment banking and trading while reducing its consumer banking presence [3] - The company completed the sale of its home-improvement lending platform GreenSky in Q1 2024 and sold its Personal Financial Management unit in H2 2023 [3] - Over the past six months, Goldman Sachs shares have increased by 39.6%, outperforming the industry growth of 35.8% [3] Market Participation - Other major banks, such as JPMorgan Chase and PNC, are also increasing their market participation, which is valued between $800 billion to $1 trillion [5] - JPMorgan has enhanced its lending functions following the acquisition of First Republic Bank in 2023, while PNC acquired loan commitments from Signature Bank worth approximately $16 billion in October 2023 [5]

Core Investment Thesis - Adding The Goldman Sachs Group, Inc. (GS) stock to a portfolio is considered a wise decision due to its fundamental strength and growth prospects, with analysts optimistic about its earnings growth potential [1] - The Zacks Consensus Estimate for GS's 2024 earnings has been revised upward by 3.7% over the past 30 days, resulting in a Zacks Rank 1 (Strong Buy) [1] Price Performance - GS stock has gained 36.9% over the past six months, outperforming the industry's growth of 32.9% [1] Strategic Focus - Goldman Sachs is refocusing on its core strengths in investment banking (IB) and trading operations while scaling back its consumer banking footprint, which includes the sale of GreenSky and offloading its credit card program with General Motors [3] - This strategic pivot aims to enhance growth in core businesses, supported by strong leadership and operational scale [3] Investment Banking Strength - In 2023, Goldman Sachs led in worldwide announced and completed mergers and acquisitions (M&As), equity offerings, and common stock offerings, providing a competitive edge [4] - Robust client engagement and a growing M&A and underwriting pipeline are expected to support IB revenues, with projected IB fee increases of 17.8% and 3.2% year over year for 2024 and 2025, respectively [4] Financial Health - As of March 31, 2024, Goldman Sachs reported cash and cash equivalents of $209 billion and total unsecured debt of $312 billion, with only $78 billion in near-term borrowings [5] - The company maintains investment-grade long-term debt ratings (A/A2/BBB+) and a stable outlook from major rating agencies, indicating a solid credit profile [5] Capital Distribution - Goldman Sachs has a strong track record of capital distribution, including a share repurchase program of up to $30 billion, with $22.7 billion remaining as of March 31, 2024 [6] - The company also announced a 10% increase in common stock dividends in July 2023, supported by decent liquidity, which is likely to boost investor confidence [6]

Core Insights - Pennybacker Capital Management has received a strategic investment from Goldman Sachs Asset Management's Petershill program, although the terms of the transaction were not disclosed [1] - This investment will enable Pennybacker to enhance its platform as a leading middle-market real assets investment manager [1] - The CEO of Pennybacker expressed optimism about the growth potential and the partnership with Goldman Sachs [1] Company Overview - Pennybacker is a real assets investment management firm based in Austin, Texas, managing approximately $4 billion in assets [2] - The firm focuses on real estate and infrastructure strategies through both closed-end and open-ended vehicles across the capital structure [2] Goldman Sachs Asset Management Overview - Goldman Sachs is a leading global investor in alternatives, with over $450 billion in assets and more than 30 years of experience [3] - The firm invests across a wide range of alternative assets, including private equity, growth equity, private credit, real estate, infrastructure, hedge funds, and sustainability [3] - As of December 31, 2023, Goldman Sachs has over $2.8 trillion in assets under supervision globally [3] Petershill Program Overview - Established in 2007, the Petershill program partners with leading alternative asset managers to accelerate their strategic development [4] - The program's minority investments aim to create long-term value by providing strategic capital for employee retention, business development, and other strategic options while maintaining the autonomy of the organizations [4]

Core Insights - Attovia Therapeutics has successfully closed a $105 million oversubscribed Series B financing, increasing total capital raised to $165 million since its inception in June 2023 [1][2] Financing Details - The Series B financing was led by Goldman Sachs Alternatives, with participation from both new and existing investors including Cormorant Asset Management, Nextech Ventures, Redmile Group, EcoR1 Capital, Marshall Wace, and Logos Capital [2] - Existing investors such as Frazier Life Sciences, venBio, and Illumina Ventures also participated in this financing round [2] - Colin Walsh, Ph.D., from Goldman Sachs Alternatives, has been appointed to Attovia's Board of Directors concurrent with the financing [2] Company Strategy and Pipeline - The proceeds from the financing will be utilized to advance lead programs ATTO-1310 and ATTO-002 through initial clinical data readouts, expand the immunology and inflammation pipeline, and further develop the ATTOBODY™ platform [1][3] - ATTO-1310 is positioned as a potential first-in-class anti-IL31 ATTOBODY, currently in IND enabling studies, expected to enter clinical trials by the end of 2024 for treating atopic dermatitis and other pruritic diseases [3] - ATTO-002, a bispecific anti-IL31 x IL13 ATTOBODY, is anticipated to have a development candidate nominated in the second half of 2024, with plans to advance to IND in 2025 [3] - The company is also working on discovery stage programs to expand the ATTOBODY platform to novel, difficult-to-drug targets [3] Technology and Product Development - Attovia's ATTOBODY™ platform generates spatially optimized biparatopic biologics, which are designed to offer stronger efficacy and a broader range of druggable epitopes compared to traditional methods [5][6] - The biparatopic binding mode of ATTOBODIES provides picomolar affinity and strong potency, with the ability to functionalize biologically inactive epitopes [6] - The platform allows for modular engineering into multispecifics and offers tunable half-lives from hours to weeks, significantly accelerating development and expanding target biology coverage [6] Market Position and Future Outlook - Attovia is positioned to become a leader in developing best-in-class novel biologics for immune-mediated diseases, leveraging its differentiated pipeline and proprietary platform [4][3] - The strong investor interest reflects the rapid progress made since the company's inception and the potential for future business development opportunities [3][4]